Effect of MitoQ on Platelet Function and Reactive Oxygen Species (ROS) Generation in Patients With Sickle Cell Anemia

About the study

MitoQ is commercially available as a dietary supplement and it has been tested as a potential
drug in other diseases, but it has never been tested in patients with sickle cell disease.

The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by
removing potentially damaging agents in a living organism, improves platelet function in
patients with sickle cell disease (SCD).

Study point of contact

Jude Jonassaint, RN
412-692-2086
[email protected]
Mikhil N Bamne, PhD
(412) 648-6920
[email protected]

Locations

5 United States sites

Age

> 18 Years

Phase

N/A

Study type

Interventional

Gender

All

Interventions

Dietary Supplement

Compensation

Unknown

participation requirements

Subjects

– African American

– Patients with sickle cell anemia

– 18 years old or older

Control

– African American healthy controls

– 18 years of age or older

participation restrictions

1. Pregnancy,

2. Known hypertension,

3. Hemodialysis and active obstructive sleep apnea requiring treatment.

4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to
enrollment.

Locations

  • Pittsburgh, Pennsylvania, United States, Magee Women's Hospital, 15213 [Recruiting]
  • Pittsburgh, Pennsylvania, United States, UPMC Montefiore, 15213 [Recruiting]
  • Pittsburgh, Pennsylvania, United States, UPMC Presbyterian, 15213 [Recruiting]
  • Pittsburgh, Pennsylvania, United States, Children's Hospital of Pittsburgh, 15224 [Recruiting]
  • Pittsburgh, Pennsylvania, United States, Hillman Cancer Center, 15232 [Recruiting]
Last updated 2020-12-03